Prolonged overall survival in metastatic gastric cancer treated with ipilimumab and lapatinib
Related Experiment Video
Updated: Jan 31, 2026

Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
Published on: May 1, 2019
Yanfang Ju1, Shengjie Sun1, Shunchang Jiao1
1Department of Oncology, Chinese PLA General Hospital, Beijing, China.
Objective:
Gastric cancer is one of the most important common tumors in the world. It remains the second leading cause of cancer-related death worldwide. The prognosis of patients with unresectable or metastatic gastric cancer remains poor. New targeted drugs were evaluated in clinic, such as lapatinib. The potential for making beneficial progress is to investigate innovative therapeutic strategies, such as immunotherapy.
Methods:
We used combination therapy including immunotherapy for treating gastric cancer. We treated a patient of metastatic gastric cancer for which lapatinib plus ipilimumab was effective after progression on trastuzumab.
Results:
The patient has prolonged overall survival after treatment. Positron emission tomography-computed tomography examination showed that some of the cervical lymph nodes and retroperitoneal lymph nodes reduced and glucose metabolism decreased. In blood examination, the tumor marker (carcinoembryonic antigen) decreased. The patient has been lived for 4 years after multiple lymph node metastasis.
Conclusion:
Targeted therapy combined with immunotherapy might be a useful option for metastatic gastric.
Insights
Combination therapy using targeted drugs like lapatinib and immunotherapy (ipilimumab) showed promising results for a patient with metastatic gastric cancer, extending survival by four years.
Area of Science:
- Oncology
- Immunotherapy
- Gastrointestinal Oncology
Background:
- Gastric cancer is a leading cause of cancer death globally, with poor prognosis for unresectable or metastatic disease.
- Targeted therapies (e.g., lapatinib) and immunotherapies represent novel treatment avenues.
- Investigating innovative therapeutic strategies is crucial for improving patient outcomes.
Observation:
- A patient with metastatic gastric cancer progressed on trastuzumab therapy.
- The patient received combination therapy with lapatinib and ipilimumab.
- Treatment led to prolonged overall survival and positive diagnostic imaging results.
Findings:
- Positron emission tomography-computed tomography (PET-CT) revealed reduced size and glucose metabolism in metastatic lymph nodes.
- Tumor marker levels (carcinoembryonic antigen) decreased following treatment.
- The patient achieved a four-year survival period after initial diagnosis of multiple lymph node metastasis.
Implications:
- Combination therapy of targeted agents and immunotherapy may offer a viable treatment option for metastatic gastric cancer.
- This approach could potentially improve survival rates in patients with advanced disease.
- Further clinical investigation is warranted to validate these findings in a broader patient population.
Related Concept Videos
Cancer Survival Analysis
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...
Gastric Emptying
Gastric Phase of Digestion
When food enters the stomach, it stretches the stomach walls and activates stretch receptors. This triggers local reflexes of the enteric nervous system, mediated through the myenteric plexus. These...

